Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks

Metsera's shares rose as much as 20% after Phase I results for its ultra-long-acting amylin injectable, MET-233i, demonstrated an 8.4% average weight reduction in overweight or obese patients over 36 weeks, compared to placebo. Guggenheim Partners highlighted this data as a critical milestone, noting MET-233i's potential as the only once-monthly amylin in clinical development and its possible combination with Metsera's other assets. The results are seen as validating the amylin mechanism in obesity treatment, especially after Novo Nordisk's CagriSema data underwhelmed, potentially opening opportunities for competitors like Metsera in the estimated $19 billion ultra-long-acting injectable incretin therapies market by 2035.

Analysis

Metsera has reported promising Phase I results for its ultra-long-acting amylin injectable, MET-233i, demonstrating an average weight loss of 8.4% at 36 weeks in overweight or obese patients without type 2 diabetes, relative to placebo, with some individual responses reaching 10.2%. This development, which spurred up to a 20% rise in Metsera's shares, was identified by Guggenheim Partners as a "critical program milestone" capable of substantially de-risking the MET-233i program. Pharmacokinetic analysis confirmed a 19-day half-life, supporting a once-monthly dosing regimen, and MET-233i exhibited a clean safety profile with only mild, transient gastrointestinal side effects limited to the first week, suggestive of rapid tolerance and less common than with GLP-1s. Guggenheim highlights MET-233i as the sole potential once-monthly amylin in clinical development, offering pathways to differentiated products through potential combinations with Metsera's other pipeline assets targeting GIP and glucagon, within an ultra-long-acting injectable incretin market estimated by Guggenheim to reach $19 billion by 2035. These results gain further significance following Novo Nordisk's (NVO) underwhelming Phase III data for its amylin combination CagriSema, which achieved 22.7% weight loss against a 25% expectation, leading to a significant market capitalization decline for NVO. Guggenheim posited that Novo's "unforced error" in its trial dosing protocol inadvertently validated the amylin mechanism in obesity and created an opening for differentiated competitors like Metsera. Metsera plans to release topline findings from the continued MET-233i monotherapy study later this year and anticipates data from a combination trial with its GLP-1 therapy MET-097i as early as year-end 2025; data for MET-097i monotherapy is also a key upcoming readout. Other notable players in the amylin space include Eli Lilly (LLY), with Phase II eloralintide data expected mid-2025, and AbbVie (ABBV), which recently entered the field through a substantial deal.

Key Decisions for Investors

• Investors should closely monitor Metsera's upcoming catalysts, particularly the full topline Phase I data for MET-233i monotherapy expected later this year and the separate data for its ultra-long-acting GLP-1, MET-097i, identified as key value-driving readouts.
• Consider the enhanced competitive positioning of Metsera's once-monthly MET-233i, given its positive early data and the strategic window potentially opened by Novo Nordisk's (NVO) difficulties with CagriSema, which could impact future market share in obesity treatments.
• Evaluate the progress of other amylin programs, such as Eli Lilly's (LLY) eloralintide with Phase II data anticipated in mid-2025, to continuously assess the relative therapeutic and commercial potential of Metsera's asset within the evolving landscape.